Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Chennai: People whose immune systems mount an unusually aggressive early response to tuberculosis may be less likely to ...